APA (7th ed.) Citation

B, K., NC, C., P, N., J, H., E, K., S, K., . . . N, Z. (2024). Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217. Alzheimer's research & therapy, 16(1), 254. https://doi.org/10.1186/s13195-024-01620-7

Chicago Style (17th ed.) Citation

B, Kovacech, et al. "Post Hoc Analysis of ADAMANT, a Phase 2 Clinical Trial of Active Tau Immunotherapy with AADvac1 in Patients with Alzheimer's Disease, Positive for Plasma P-tau217." Alzheimer's Research & Therapy 16, no. 1 (2024): 254. https://doi.org/10.1186/s13195-024-01620-7.

MLA (9th ed.) Citation

B, Kovacech, et al. "Post Hoc Analysis of ADAMANT, a Phase 2 Clinical Trial of Active Tau Immunotherapy with AADvac1 in Patients with Alzheimer's Disease, Positive for Plasma P-tau217." Alzheimer's Research & Therapy, vol. 16, no. 1, 2024, p. 254, https://doi.org/10.1186/s13195-024-01620-7.